Last Price
0.349
Today's Change
+0.159 (83.68%)
Day's Change
0.343 - 0.554
Trading Volume
294,014,247
Market Cap
2 Million
Shares Outstanding
6 Million
Avg Volume
2,039,119
Avg Price (50 Days)
0.32
Avg Price (200 Days)
4.33
PE Ratio
0.02
EPS
21.94
Earnings Announcement
12-Nov-2024
Previous Close
0.19
Open
0.40
Day's Range
0.3382 - 0.5536
Year Range
0.18 - 52.8
Trading Volume
294,736,732
1 Day Change
78.42%
5 Day Change
61.43%
1 Month Change
8.48%
3 Month Change
-46.57%
6 Month Change
-91.63%
Ytd Change
-96.93%
1 Year Change
-99.12%
3 Year Change
-99.93%
5 Year Change
-99.86%
10 Year Change
-100.00%
Max Change
-100.00%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.